

1 Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from
2 vaccinated individuals

3

4 Johannes Hayer¹

5 Eva Urlaub¹

6

7 ¹Roche Diagnostics GmbH, Mannheim, Germany

8 Corresponding author: Eva Urlaub, Roche Diagnostics GmbH, Mannheim, Germany,

9 eva.urlaub@roche.com

10

11 **Running title**

12 SARS-CoV-2 rapid POC antibody test in a vaccinated cohort

13

14

15 **Abstract**

16 *Objective*

17 The study aimed to establish the performance of the SARS-CoV-2 Rapid Antibody
18 Test (IgG and IgM) and the Elecsys[®] Anti-SARS-CoV-2 S assay in vaccinated
19 individuals.

20 *Methods*

21 A panel of serum samples from Boca Biostatics was utilized to assess antibodies
22 following vaccination, consisting of samples drawn prior to vaccination, after the first
23 dose, or at least 14 days after the second dose of Moderna mRNA-1273 or Pfizer-
24 BioNTech BNT162b2 COVID-19 vaccines. Agreement between the two methods
25 was measured and stratified by test evaluator and assay lot.

26 *Results*

27 Agreement between the SARS-CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-
28 SARS-CoV-2 S assay qualitative measurements at the different assessment points
29 for both mRNA-1273 and BNT162b2 ranged between 97.06% (95% confidence
30 interval [CI] 84.67, 99.93) to 100% (95% CI 82.35, 100). Agreement of the SARS-
31 CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay was
32 not highly influenced by either lot or evaluator. There was a medium-to-strong
33 correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG)
34 result and quantitative Elecsys Anti-SARS-CoV-2 S assay in samples taken after
35 both doses of the vaccines, with higher intensity bands being associated with higher
36 total anti-S antibody titer (mRNA-1273, $p=0.0019$; BNT162b2, $p<0.0001$).

37 *Conclusion*

38 Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys
39 Anti-SARS-CoV-2 S assay correlated well, suggesting that the SARS-CoV-2 Rapid
40 Antibody Test (IgG) is helpful in understanding the immune response post-
41 vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody
42 Test (IgG) in the vaccinated population.

43 **Importance**

44 Serologic assays are an essential tool for seroprevalence surveys, for quality control
45 of vaccines, and to determine the response to vaccination. Although a correlate of
46 immunity has not yet been established for COVID-19 vaccines, antibody titers after
47 natural infection and vaccination have been associated with protection from
48 symptomatic SARS-CoV-2 infection. Rapid point-of-care assays can be of use in this
49 context with advantages over centralized testing, such as speed and ease of use.
50 The point-of-care SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the
51 Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one or
52 two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2. Semi-
53 quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-
54 SARS-CoV-2 S assay results correlated well, suggesting that SARS-CoV-2 Rapid
55 Antibody Test (IgG) is helpful in understanding the immune response post-
56 vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody
57 Test (IgG) in the vaccinated population.

58 **Keywords**

59 antibodies, neutralizing; COVID-19 vaccines; immunity; immunoassay; nucleocapsid
60 protein; point-of-care systems; SARS-CoV-2; spike protein

61

62 **Introduction**

63 Serologic immunoassays are vital in the global management of the COVID-19
64 pandemic. Measurement of antibodies to SARS-CoV-2 is important for improving
65 disease management, and accurate tests, with validated sensitivity and specificity,
66 are essential for obtaining reliable results when monitoring the pandemic via
67 seroprevalence surveys (1). Serologic assays can provide evidence of recent or past
68 infection (2), and identify those individuals still at risk of infection (3).

69 Infection with SARS-CoV-2 elicits a strong neutralizing antibody response (4), and
70 antibodies that bind via the spike protein act as neutralizing antibodies (5, 6). Several
71 studies have shown good correlation between anti-S antibodies and functional virus
72 neutralization (7–11). Neutralization assays utilizing live virus require biosafety level
73 3 containment, which can be labor intensive and low throughput (12–14); therefore
74 anti-S immunoassays, as a surrogate for neutralization, have an important role to
75 play (13, 15). On an individual patient level, anti-S immunoassays can confirm
76 vaccination status or inform upon the need for booster doses (16), which may be
77 helpful for both social and medical reasons.

78 Moderna mRNA-1273 (spikevax™) and Pfizer-BioNTech BNT162b2 (COMIRNATY®)
79 COVID-19 vaccines are mRNA vaccines, approved under the U.S. Food and Drug
80 Administration's emergency use authorization, each employing a two-dose regimen
81 (17, 18). The immune response involves B cells that produce binding and
82 neutralizing antibodies against the SARS-CoV-2 S protein (19, 20) and both
83 vaccines encode the SARS-CoV-2 spike protein to generate an immune response.
84 Serologic assays are an essential tool in vaccine quality control, being used to
85 determine the response to vaccination and providing insight into the antibody
86 response from the individual patient perspective (21, 22).

87 The Elecsys[®] Anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd,
88 Rotkreuz, Switzerland) is an electrochemiluminescence immunoassay (ECLIA),
89 which has been developed for quantitative *in vitro* detection of antibodies in human
90 serum and plasma (23). The assay detects total antibodies, including
91 immunoglobulin G (IgG), against the receptor binding domain (RBD) of the SARS-
92 CoV-2 spike protein, and is intended for use on the fully automated and high-
93 throughput cobas e analyzers (23). The assay has been shown to detect anti-S
94 antibodies across a variety of different populations (2, 24), and has been utilized as a
95 surrogate of neutralization activity (11, 25).

96 The SARS-CoV-2 Rapid Antibody Test (Roche Diagnostics International Ltd,
97 Rotkreuz, Switzerland) is CE-marked rapid chromatographic immunoassay intended
98 for the qualitative *in vitro* detection of both IgM and IgG antibodies to SARS-CoV-2
99 spike or nucleocapsid proteins in human serum, plasma or whole blood, for
100 professional use in the laboratory and at point-of-care (26). A study utilizing real-
101 world clinical samples in unvaccinated individuals demonstrated that the SARS-CoV-
102 2 Rapid Antibody Test had comparable performance with the Elecsys Anti-SARS-
103 CoV-2 assay that targets the nucleocapsid protein (27).

104 The objective of this study was to establish the performance of the SARS-CoV-2
105 Rapid Antibody Test and the Elecsys Anti-SARS-CoV-2 S assay in serum samples
106 obtained from individuals who had received a COVID-19 vaccination.

107 **Materials and Methods**

108 *Study design*

109 The study was a retrospective performance study conducted at Roche Diagnostics
110 GmbH (Mannheim, Germany). All samples were analyzed with the SARS-CoV-2

111 Rapid Antibody Test and compared with the Elecsys Anti-SARS-CoV-2 S assay.

112 Tests were conducted as per manufacturer's instructions (23).

113 *Samples*

114 To assess antibodies following vaccination, a post-vaccination panel was prepared
115 using 74 serum samples obtained from Boca Biolistics (Florida, USA), collected
116 between February and April 2021, and stored at -20°C or colder (all available
117 samples at the time of request). Serum samples were from individuals from the USA
118 sampled prior to vaccination, after the first dose, or at least 14 days after the second
119 dose of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (Supplemental Table
120 1).

121 Samples were separated into aliquots of 50 µL for the SARS-CoV-2 Rapid Antibody
122 Test measurement and 200 µL for the Elecsys Anti-SARS-CoV-2 S reference
123 measurement on the cobas[®] 6000 and stored at -80°C until use.

124 An in-house panel of 15 negative serum samples, previously determined negative by
125 Elecsys Anti-SARS-CoV-2 S assay, was utilized to assess the specificity of the
126 SARS-CoV-2 Rapid Antibody Test. Samples were collected in June 2021 as part of
127 an in-house blood donation service at Roche Diagnostics (Mannheim, Germany),
128 anonymized, and stored at -80°C until use. No information about vaccination status
129 was available. Evaluators were blinded as to the origin of the samples. Cross-
130 reactivity to other pathogens was not analyzed in this study as this has been
131 evaluated elsewhere (26, 27).

132 *SARS-CoV-2 Rapid Antibody Test*

133 The SARS-CoV-2 Rapid Antibody Test detects the presence of SARS-CoV-2 IgM
134 and IgG antibodies, and the intensity of the test line is dependent upon the level of

135 SARS-CoV-2 antibodies present in the sample (26). In unvaccinated individuals, the
136 reported sensitivity is 92.59% (7–14 days post-symptom onset [POS]) and 99.03%
137 (>14 days POS), with specificity of 98.65% (26).

138 Each sample was tested with two different lots of the SARS-CoV-2 Rapid Antibody
139 Test. The readout was visually assessed at 10 minutes by two different independent
140 evaluators; these evaluators were not the operators who had performed the test. In
141 accordance with manufacturer's instructions, the sample was considered positive if
142 the control line and at least one colored band/test line at G or M became apparent
143 (qualitative determination). As an exploratory analysis, results were further defined
144 by the intensity of the band to provide semi-quantitative data (Supplemental Table
145 2), with the signal intensity being rated according to a color scale. Data are
146 presented separated by lot and by evaluator. In the event of an invalid result, the test
147 would be repeated.

148 *Elecsys Anti-SARS-CoV-2 S assay*

149 The Elecsys Anti-SARS-CoV-2 S assay results are reported automatically as the
150 analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as
151 negative and ≥ 0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies
152 (23). The reported sensitivity and specificity of this test 14 days post-PCR is 97.92%
153 and 99.95%, respectively (24). The quantification range is between 0.4 and 250
154 U/mL and the reported limit of detection is 0.35 U/mL (23). If the sample
155 concentration is >250 U/mL, the sample can be diluted up to 1:100; in these cases,
156 the final result is determined as >25,000 U/mL (23).

157 In the event of an invalid result, the test would be repeated. All samples were
158 measured in duplicate, and the result calculated as the arithmetic mean of both

159 replicates. Assessors were blinded to the SARS-CoV-2 Rapid Antibody Test results
160 and blinded as to the origin of the samples.

161 *Statistical analysis*

162 The agreement rates comparing the SARS-CoV-2 Rapid Antibody Test with Elecsys
163 Anti-SARS-CoV-2 S assay per vaccine type were calculated per lot. Two-sided 95%
164 Clopper–Pearson confidence intervals (CI) for the agreement rates are given.

165 Correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test data
166 and quantitative Elecsys Anti-SARS-CoV-2 S assay data was assessed using the
167 Kendall's rank correlation τ . Accuracy of the SARS-CoV-2 Rapid Antibody Test result
168 — how often do the qualitative results agree with one another — was assessed by
169 lot and evaluator. Statistical analyses were conducted using R (version 3.6.3) and
170 JMP (version 15).

171 **Results**

172 Overall, the study cohort consisted of 56 predominantly white/Caucasian individuals
173 (median age 70 years; 55.36% female) with a variety of pre-existing medical
174 conditions (Table 1). No invalid results were generated using either test.

175 *Analyses of the SARS-CoV-2 Rapid Antibody Test (qualitative) with the Elecsys Anti-* 176 *SARS-CoV-2 S assay (quantitative and qualitative)*

177 Eight samples were obtained from patients who were sampled prior to vaccination.
178 Whilst only two patients were reported to have been previously diagnosed with
179 COVID-19, only one patient was IgG and IgM negative (by both the SARS-CoV-2
180 Rapid Antibody Test and Elecsys Anti-SARS-CoV-2 S assay). For the seven positive
181 samples, Elecsys Anti-SARS-CoV-2 S total antibody titers ranged from 254.0 U/mL

182 to >25,000 U/mL and all were identified as positive by the SARS-CoV-2 Rapid
183 Antibody Test.

184 The post-vaccination antibody analysis included 25 samples from individuals
185 vaccinated with mRNA-1273 and 42 vaccinated with BNT162b2. The dosing interval
186 between first and second vaccine doses for BNT162b2 was a median of 21 days
187 (minimum 19 days, maximum 23 days) and a median of 28 days (minimum 21 days,
188 maximum 32 days) for mRNA-1273. There was good agreement between the SARS-
189 CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-SARS-CoV-2 S qualitative
190 measurements at the different assessment points for both the Moderna and Pfizer-
191 BioNTech vaccines ranging from 97.06% (95% CI 84.67, 99.93) to 100% (95% CI
192 89.72, 100) (Table 2). There was one false-negative sample with evaluator 2 (after
193 second dose of BNT162b2, lot 1 and lot 2), however this sample was classified as
194 positive by evaluator 1.

195 There was poor agreement between the SARS-CoV-2 Rapid Antibody Test (IgM)
196 and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different
197 assessment points for both BNT162b2 and mRNA-1273 ranging from 14.71% (95%
198 CI 4.95, 31.06) to 80.00% (95% CI 28.36, 99.49) with many false-negatives (Table
199 2).

200 Using the in-house negative panel, there were no false-positive results for either lot
201 or evaluator (**Error! Reference source not found.**).

202 *Analyses of the SARS-CoV-2 Rapid Antibody Test (semi-quantitative) with the*
203 *Elecsys Anti-SARS-CoV-2 S assay (quantitative)*

204 There was a medium-to-strong correlation between the semi-quantitative SARS-
205 CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S

206 assay in samples taken after both doses of the vaccines (Figure 1), with higher
207 intensity bands being associated with higher total anti-S antibody titer (with Kendall's
208 τ up to 0.599 for IgG mRNA-1273 [$p=0.0019$] and 0.6833 [$p<0.0001$] for IgG
209 BNT162b2) (**Error! Reference source not found.**). There was no correlation
210 between the quantitative Elecsys Anti-SARS-CoV-2 S assay result and the intensity
211 of the SARS-CoV-2 Rapid Antibody Test (IgM) (**Error! Reference source not
212 found.**).

213 Agreement between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgM)
214 and quantitative Elecsys Anti-SARS-CoV-2 S assay was poor, with many samples
215 designated as negative on the SARS-CoV-2 Rapid Antibody Test (IgM) even in the
216 presence of high anti-S antibody titers (Results from the SARS-CoV-2 Rapid
217 Antibody Test were classified as negative or one of the five levels of increasing
218 positivity based upon line intensity (((+)), (+), +, ++ or +++). Maximum value
219 attainable by the Elecsys Anti-SARS-CoV-2 assay was 25,000 U/mL. Higher values
220 are indicated as >25,000 U/mL. Blue = Lot 1; red = Lot 2; ○ = Evaluator 1; + =
221 Evaluator 2.

222

223 Figure 2).

224 *Accuracy of the SARS-CoV-2 Rapid Antibody Test*

225 Comparison of the SARS-CoV-2 Rapid Antibody Test (IgG) results by lot or
226 evaluator revealed that these factors did not influence the results, with a minimum
227 accuracy estimate of 97.06% (**Error! Reference source not found.**).

228 SARS-CoV-2 Rapid Antibody Test (IgM) positivity appeared to be influenced by
229 evaluator, with a minimum accuracy estimate of 40% and considerable variability in
230 accuracy estimates across the different time points and vaccines (**Error! Reference
231 source not found.**).

232 *Evaluation of Elecsys Anti-SARS-CoV-2 S assay titer post-vaccination*

233 Antibody titers by days following final vaccination are shown in Figure 3. Following
234 complete vaccination with BNT162b2 or mRNA-1273 and up to approximately 20
235 days, there was significant variability with both high (maximum >25,000 U/mL) and
236 low (minimum 238.2 U/mL for BNT162b2 and 340.2 U/mL for mRNA-1273) anti-S
237 titers. After 30 days, anti-S titers for both vaccines commonly declined to below
238 5,000 U/mL (overall minimum 13.53 U/mL 25 days after vaccination with BNT162b2).

239 The median time between final vaccination and final measurement for those
240 vaccinated with BNT162b2 was 18 days (minimum 14 days, maximum 44 days) and
241 46 days (minimum 14 days, maximum 65 days) for mRNA-1273. Anti-S antibody
242 titers were numerically higher in participants vaccinated mRNA-1273 (median 2,307
243 U/mL; interquartile range [IQR] 872–6,845) than in those who received BNT162b2
244 (median 1,601 U/mL; IQR 467–3,131).

245 *Longitudinal analysis*

246 A small number of individuals had samples available from all three time points
247 (BNT162b2 cohort), allowing longitudinal evaluation of anti-S antibody titer levels; all
248 except one showed high levels of anti-S antibody titers at the first time point (prior to
249 vaccination). There was considerable variance in the effect of vaccination upon anti-
250 S antibody titers, however the greatest change was for the individual who was
251 infection-naïve (<0.4 U/mL to 1,645 U/mL following the second dose). For five out of
252 eight individuals, including those with previously diagnosed COVID-19, anti-S
253 antibody titers decreased over time despite vaccination with BNT162b2 (**Error!**
254 **Reference source not found.**).

255 **Discussion**

256 Serologic assays are an essential tool for quality control of vaccines and to
257 determine the response to vaccination. Although a correlate of immunity has not yet
258 been established for COVID-19 vaccines, antibody titers after natural infection and
259 vaccination have been associated with protection from symptomatic SARS-CoV-2
260 infection (28); and rapid point-of-care assays can potentially be of use in this setting
261 with particular advantages over centralized testing, such as speed and ease of use.

262 We evaluated the use of the SARS-CoV-2 Rapid Antibody Test in vaccinated
263 individuals in comparison with the Elecsys Anti-SARS-CoV-2 S assay.

264 Our results indicate that the Elecsys Anti-SARS-CoV-2 S assay detects anti-S
265 antibodies after the first dose of both BNT162b2 and mRNA-1273, in agreement with
266 previous studies of the adaptive humoral response to vaccination in various
267 populations (21, 22, 29–33).

268 Whilst the performance of rapid antibody tests has been reported in unvaccinated
269 individuals (34–36), no studies have yet reported upon their use in vaccinated

270 individuals. The SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the
271 Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one
272 dose and two doses, similar to what has been observed in unvaccinated individuals
273 (27). Assessment of the influence of lot or evaluator revealed that agreement of the
274 SARS-CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay
275 was not highly influenced by either factor, suggesting that the SARS-CoV-2 Rapid
276 Antibody Test (IgG) is robust under normal usage conditions.

277 There was low agreement of the SARS-CoV-2 Rapid Antibody Test (IgM) with the
278 Elecsys Anti-SARS-CoV-2 S assay because, in general, there is a lower sensitivity
279 for IgM compared with IgG for point-of-care lateral flow assays, as exemplified in a
280 recent analysis of healthcare workers vaccinated with the first dose of the Pfizer
281 vaccine and sampled 21–24 days thereafter (37). In addition, the Elecsys Anti-
282 SARS-CoV-2 S assay preferentially detects high-affinity IgG antibodies that compete
283 with IgM antibodies (23), contributing to the lower agreement rates with IgM results.
284 In agreement with previous research on the use of lateral flow assays in
285 unvaccinated individuals (38, 39), we also report lower evaluator concordance when
286 reading IgM compared with IgG bands. Jones and colleagues found that IgM bands
287 are often weak positives (39), consistent with our data in vaccinated individuals,
288 potentially resulting in an increased likelihood of a miscall and contributing to the low
289 reader agreement.

290 The vaccines were administered in accordance with the relevant primary dosing
291 schedules, with approximately 3 weeks for BNT162b2 and 1 month for mRNA-1273
292 between doses (17, 18). Whilst the data reported herein suggest some variation in
293 the level of antibody titers afforded by the vaccines, two doses of either mRNA-1273
294 or BNT162b2 induced high levels of anti-S antibodies. Anti-S total antibody titers

295 were higher in participants vaccinated with mRNA-1273 than BNT162b2, in
296 accordance with previous publications (40). Whilst the clinical significance of
297 quantitative differences in antibody titers following COVID-19 vaccination have not
298 yet been established, understanding the differences in antibody titer can support
299 individual choices and assist with policy decisions.

300 The longitudinal analysis revealed that five individuals in the BNT162b2 cohort
301 appeared to have previously undiagnosed SARS-CoV-2 infection prior to
302 vaccination, and the effect of vaccination upon anti-S antibody titers in this group at
303 the individual level was highly variable (relative decrease or increase after the first
304 dose). Overall, after primary vaccination with two doses, all except one of those with
305 previous natural infection had higher anti-S antibody titers than the infection-naïve
306 participant, in agreement with previous reports which support higher titers following
307 vaccination in previously infected individuals (40–42).

308 The findings of this study are subject to several limitations. The performance of the
309 SARS-CoV-2 Rapid Antibody Test in vaccinated individuals was based on the
310 evaluation of a relatively small panel of samples and utilized only two vaccines.
311 However, the cohort tested was generally representative of an aged US population,
312 with hypertension and diabetes mellitus in line with age-related expectations of
313 prevalence (43, 44). Whilst the median anti-S antibody titers induced by vaccination
314 differed between those vaccinated with BNT162b2 or mRNA-1273, the majority of
315 the post-vaccination BNT162b2 samples were collected earlier than samples
316 collected for mRNA-1273, there were more data points for BNT162b2, and the data
317 for mRNA-1273 samples spanned a longer time frame (last sample was post 60
318 days for mRNA-1273 compared with <45 days for BNT162b2). Furthermore, most of

319 the samples used in the longitudinal analysis were from positive pre-vaccinated
320 individuals, which limits our findings.

321 The clinical relevance of semi-quantitative results is currently unknown and, at
322 present, cannot be interpreted as an indication of varying levels of immunity. In
323 addition, semi-quantitative evaluation of the intensity of the bands is determined by
324 the reader and therefore subjective, even with the use of a color scale guide and
325 training. The performance of the SARS-CoV-2 Rapid Antibody Test seen herein can
326 also not be extrapolated to immunocompromised individuals whose immune
327 response post vaccination may be more variable (45). However, semi-quantitative
328 SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2
329 S assay results correlated well, suggesting that SARS-CoV-2 Rapid Antibody Test
330 (IgG) is helpful in understanding the immune response post vaccination, particularly
331 in the absence of centralized and fully automated testing systems. The current data
332 support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) in the vaccinated
333 population.

334 **Conflicts of interest**

335 All authors have completed the ICMJE uniform disclosure form at
336 www.icmje.org/coi_disclosure.pdf and declare: that JH and EU are employees of
337 Roche Diagnostics; EU participates in Roche Connect; no other relationships or
338 activities that could appear to have influenced the submitted work.

339 **Ethical approval and consent**

340 Anonymized samples were provided by the commercial supplier Boca Biologics and
341 collected under their ethical approval system. Ethical approval for the in-house panel
342 was provided by Ethik-Kommission II der Universität Heidelberg, Medizinische

343 Fakultät, Mannheim, Germany. Samples were anonymized, and collected and tested
344 in accordance with applicable regulations, including relevant European Union
345 directives and regulations, and the principles of the Declaration of Helsinki.

346 **Data availability**

347 Qualified researchers may request access to individual anonymized patient-level
348 data through the clinical study data request platform (<https://vivli.org/>). Further details
349 on Roche's criteria for eligible studies are available here:
350 <https://vivli.org/members/ourmembers/>. For further details on Roche's Global Policy
351 on the Sharing of Clinical Information and how to request access to related clinical
352 study documents, see here:
353 [https://www.roche.com/research_and_development/who_we_are_how_we_work/clin
354 ical_trials/our_commitment_to_data_sharing.htm](https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

355 **Funding**

356 Roche Diagnostics GmbH (Mannheim, Germany) provided financial support for the
357 study and for preparation of the article. Roche Diagnostics GmbH was involved in
358 the study design; in the collection, analysis and interpretation of data; in the writing of
359 the report; and in the decision to submit the article for publication. Medical writing
360 support was funded by Roche Diagnostics GmbH.

361 **Acknowledgements**

362 Medical writing support was provided by Corrinne Segal, Elements Communications
363 Ltd, Westerham, UK. The authors would like to thank Rabea Held, Regina Draude,
364 Maureen Adamietz, Shervan Horo, and Jlenia Marconi of Roche Diagnostics for their
365 contribution to the study. COBAS, COBAS E, and ELECSYS are trademarks of
366 Roche. All other product names and trademarks are the property of their respective

367 owners'. The specific application (use in vaccinated individuals) is currently outside
368 of the intended use of the SARS-CoV-2 Rapid Antibody Test. The Elecsys Anti-
369 SARS-CoV-2 S assay is approved under an Emergency Use Authorization in the US.

370

371

372 **References**

- 373 1. Krammer F, Simon V. 2020. Serology assays to manage COVID-19. *Science*
374 368:1060–1061.
- 375 2. Riester E, Majchrzak M, Mühlbacher A, Tinguely C, Findeisen P, Hegel JK,
376 Laimighofer M, Rank CM, Schönfeld K, Langen F, Laengin T, Niederhauser C.
377 2021. Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2
378 immunoassay as an aid in determining previous exposure to SARS-CoV-2. *Infect*
379 *Dis Ther* doi:10.1007/s40121-021-00504-9:1–17.
- 380 3. Alter G, Seder R. 2020. The power of antibody-based surveillance. *N Engl J Med*
381 383:1782–1784.
- 382 4. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW,
383 Chan KH, Cheng SMS, Perera R, Cowling BJ, Poon LLM, Peiris M. 2021.
384 Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun* 12:63.
- 385 5. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S,
386 Vincent SP, Soumillion P, Alsteens D. 2020. Molecular interaction and inhibition
387 of SARS-CoV-2 binding to the ACE2 receptor. *Nat Commun* 11:4541.
- 388 6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the
389 recognition of SARS-CoV-2 by full-length human ACE2. *Science* 367:1444–1448.
- 390 7. Bal A, Pozzetto B, Traubad MA, Escuret V, Rabilloud M, Langlois-Jacques C,
391 Paul A, Guibert N, D'Aubarède-Frieh C, Massardier-Pilonchery A, Fabien N,
392 Goncalves D, Boibieux A, Morfin-Sherpa F, Pitiot V, Gueyffier F, Lina B, Fassier
393 JB, Trouillet-Assant S. 2021. Evaluation of high-throughput SARS-CoV-2

394 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical
395 sensitivity, specificity, and association with virus neutralization test. *Clin Chem*
396 67:742–752.

397 8. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA,
398 Pallavicini L, Chinali A, Campisi D, Percivalle E, DiNapoli AP, Perno CF, Baldanti
399 F. 2020. Clinical and analytical performance of an automated serological test that
400 identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. *J Clin*
401 *Microbiol* 58:e01224–20.

402 9. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire
403 J, Clearly S, Furrrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatzioannou
404 T, Jenks S, Bieniasz PD. 2021. Longitudinal serological analysis and neutralizing
405 antibody levels in coronavirus disease 2019 convalescent patients. *J Infect Dis*
406 223:389–398.

407 10. Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M,
408 Witt V, Schistal E, Schlenke P, Kreil TR, Jungbauer C. 2020. Quantification of
409 SARS-CoV-2 antibodies with eight commercially available immunoassays. *J Clin*
410 *Virol* 129:104540.

411 11. Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, Wölfel R, Gierl P,
412 Müller K, Jochum S, Strobl M, Hoelscher M, Wieser A. 2021. In search of the
413 SARS-CoV-2 protection correlate: Head-to-head comparison of two quantitative
414 S1 assays in pre-characterized oligo-/asymptomatic patients. *Infect Dis Ther*
415 10:1505–1518.

- 416 12. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q,
417 Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and
418 validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg*
419 *Microbes Infect* 9:680–686.
- 420 13. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS,
421 Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I,
422 Arinsburg S, Bandres JC, Siddiquey MNA, Schilke RM, Woolard MD, Zhang H,
423 Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Gamarnik AV, Hioe CE,
424 Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2021. Quantifying
425 absolute neutralization titers against SARS-CoV-2 by standardized virus
426 neutralization assay allows for cross-cohort comparisons of COVID-19 sera.
427 *mBio* 12:e02492–20.
- 428 14. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E,
429 Rouphael N, Edupuganti S, Shi PY, Menachery VD, Wrammert J, Suthar MS.
430 2020. Development of a rapid focus reduction neutralization test assay for
431 measuring SARS-CoV-2 neutralizing antibodies. *Curr Protoc Immunol* 131:e116.
- 432 15. Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B,
433 Pajon R. 2021. Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19
434 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial. *medRxiv*
435 doi:10.1101/2021.10.04.21264521:2021.10.04.21264521.
- 436 16. Baldanti F, Ganguly N, Wang G, Möckel M, O’Neill L, Renz H, Eduardo dos
437 Santos Ferreira C, Tateda K, Van Der Pol B. 2021. Deployment of SARS-CoV-2

- 438 diagnostic testing: challenges and key considerations for the future. Clin Rev Lab
439 Sci [submitted].
- 440 17. Pfizer-BioNTech. 2021. Fact sheet for healthcare providers administering
441 vaccine (vaccination providers): emergency use authorization (EUA) of the
442 Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019
443 (COVID-19). <https://www.fda.gov/media/153713/download>. Accessed 26 Nov
444 2021.
- 445 18. Moderna TX. 2021. Fact sheet for healthcare providers administering vaccine
446 (vaccination providers): emergency use authorization (EUA) of the moderna
447 COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19).
448 <https://www.fda.gov/media/144637/download>. Accessed 26 Nov 2021.
- 449 19. Widge AT, Roupheal NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M,
450 Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B,
451 Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B,
452 Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W,
453 Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH. 2021. Durability
454 of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 384:80–
455 82.
- 456 20. Mrak D, Tobudic S, Koblichke M, Graninger M, Radner H, Sieghart D, Hofer P,
457 Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle
458 JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. 2021. SARS-CoV-2 vaccination
459 in rituximab-treated patients: B cells promote humoral immune responses in the
460 presence of T-cell-mediated immunity. Ann Rheum Dis 80:1345–1350.

- 461 21. Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G,
462 Woclawek-Potocka I, Lukaszuk A, Rabalski L. 2021. Usefulness of IVD kits for
463 the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to
464 vaccination. *Vaccines* 9:840.
- 465 22. Salvagno GL, Henry BM, di Piazza G, Pighi L, De Nitto S, Bragantini D,
466 Gianfilippi GL, Lippi G. 2021. Anti-SARS-CoV-2 receptor-binding domain total
467 antibodies response in seropositive and seronegative healthcare workers
468 undergoing COVID-19 mRNA BNT162b2 Vaccination. *Diagnostics* 11:832.
- 469 23. Roche Diagnostics. 2021. Elecsys® Anti-SARS-CoV-2 S, instructions for use
470 (09289275190, V3.0, Dec 2021).
- 471 24. Riestler E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, Pessl F,
472 Laenglin T, Niederhauser C. 2021. Performance evaluation of the Roche Elecsys
473 Anti-SARS-CoV-2 S immunoassay. *J Virol Methods* 297:114271.
- 474 25. Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. 2021. Performance
475 of the rapid high-throughput automated electrochemiluminescence immunoassay
476 targeting total antibodies to the SARS-CoV-2 spike protein receptor binding
477 domain in comparison to the neutralization assay. *J Clin Virol* 139:104820.
- 478 26. Roche Diagnostics/SD BioSensor. 2020. SARS-CoV-2 Rapid Antibody Test,
479 instructions for use (9901-NCOV-02C, V2.0, Sept 2020).
- 480 27. Findeisen P, Stiegler H, Lopez-Calle E, Schneider T, Urlaub E, Hayer J,
481 Zemmrich C. 2021. Clinical performance evaluation of a SARS-CoV-2 Rapid

- 482 Antibody Test for determining past exposure to SARS-CoV-2. *Int J Infect Dis*
483 103:636–641.
- 484 28. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao
485 K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are
486 highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
487 *Nat Med* 27:1205–1211.
- 488 29. Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice
489 R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb
490 CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum
491 S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T. 2021. Infliximab is
492 associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-
493 19 SARS-CoV-2 vaccines in patients with IBD. *Gut* 70:1884–1893.
- 494 30. Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, Maggiolo F.
495 2021. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in
496 subjects with previous SARS-CoV-2 infection. *J Med Virol* 93:4612–4615.
- 497 31. Cavalcanti E, Isgrò MA, Rea D, Di Capua L, Trillò G, Russo L, Botti G, Miscio L,
498 Buonaguro FM, Bianchi AAM. 2021. Vaccination strategy and anti - SARS-CoV-
499 2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale"
500 Cancer Center (Naples, Italy). *Infect Agent Cancer* 16:32.
- 501 32. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T,
502 Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. 2021. Efficacy of the

- 503 BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic
504 leukemia. *Blood* 137:3165–3173.
- 505 33. Seyahi E, Bakhdıyarlı G, Oztas M, Kuskucu MA, Tok Y, Sut N, Ozcifci G,
506 Ozcaglayan A, Balkan, II, Saltoglu N, Tabak F, Hamuryudan V. 2021. Antibody
507 response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated
508 diseases: a controlled study among hospital workers and elderly. *Rheumatol Int*
509 41:1429–1440.
- 510 34. Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, Prostko J, Nebbia G,
511 Douthwaite S, Rodgers M, Cloherty G. 2020. A comparative evaluation between
512 the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™
513 SARS CoV-2 IgG assay. *J Clin Virol* 132:104645.
- 514 35. Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, Yang
515 D, Gelfand J, Bernstein BE, Feldman J, Hauser BM, Caradonna TM, Alter G,
516 Murali MR, Jasrasaria R, Quinlan J, Xerras DC, Betancourt JR, Louis DN,
517 Schmidt AG, Lennerz J, Poznansky MC, Iafrate AJ. 2020. High seroprevalence
518 of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. *J Infect Dis*
519 222:1955–1959.
- 520 36. Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E,
521 Mai AL, Gilmour KC, Hatcher J, Scott C, Randell P, Mughal N, Jones R, Moore
522 LSP, Davies GW. 2020. Point-of-care serological assays for delayed SARS-CoV-
523 2 case identification among health-care workers in the UK: A prospective
524 multicentre cohort study. *Lancet Respir Med* 8:885–894.

- 525 37. Saluzzo F, Mantegani P, Poletti De Chaurand V, Quaresima V, Cugnata F, Di
526 Serio C, Macé A, De Vos M, Sacks JA, Cirillo DM. 2021. SARS-CoV-2 Antibody
527 Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. *Microbiol*
528 *Spectr* 9:e0025021.
- 529 38. Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, Rathore U,
530 Goldgof GM, Whitty C, Woo JM, Gallman AE, Miller TE, Levine AG, Nguyen DN,
531 Bapat S P, Balcererek J, Bylsma SA, Lyons AM, Li S, Wong AW, Gillis-Buck EM,
532 Steinhart ZB, Lee Y, Apathy R, Lipke MJ, Smith JA, Zheng T, Boothby IC, Isaza
533 E, Chan J, Acenas DD 2nd, Lee J, Macrae TA, Kyaw TS, Wu D, Ng DL, Gu W,
534 York VA, Eskandarian HA, Callaway PC, Warriar L, Moreno ME, Levan J, Torres
535 L, Farrington LA, Loudermilk RP, Koshal K, Zorn KC, Garcia-Beltran WF, Yang
536 D, Astudillo MG, Bernstein BE, Gelfand JA, Ryan ET, Charles RC, Iafrate AJ,
537 Lennerz JK, Miller S, Chiu CY, Stramer SL, Wilson MR, Manglik A, Ye CJ,
538 Krogan NJ, Anderson MS, Cyster JG, Ernst JD, Wu AHB, Lynch KL, Bern C, Hsu
539 PD, Marson A. 2020. Evaluation of SARS-CoV-2 serology assays reveals a
540 range of test performance. *Nat Biotechnol* 38: 1174–1183.
- 541 39. Jones HE, Mulchandani R, Taylor-Phillips S, Ades AE, Shute J, Perry KR,
542 Chandra NL, Brooks T, Charlett A, Hickman M, Oliver I, Kaptoge S, Danesh J, Di
543 Angelantonio E, Wyllie D. Accuracy of four lateral flow immunoassays for anti
544 SARS-CoV-2 antibodies: a head-to-head comparative study. 2021. *EBioMedicine*
545 68: 103414.
- 546

- 547 40. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. 2021. Comparison of
548 SARS-CoV-2 antibody response following vaccination with BNT162b2 and
549 mRNA-1273. *JAMA* 326:1533–1535.
- 550 41. Di Meo A, Miller JJ, Fabros A, Brinc D, Hall V, Pinzon N, Ierullo M, Ku T, Ferreira
551 VH, Kumar D, Pasic MD, Kulasingam V. 2021. Evaluation of three anti-SARS-
552 CoV-2 serologic immunoassays for post-vaccine response. *J Appl Lab Med* Aug
553 3:jfab087.
- 554 42. Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S,
555 Apostolakou F, Sklirou AD, Gavriatopoulou M, Skourti S, Kastritis E, Korompoki
556 E, Papassotiriou I, Dimopoulos MA. 2021. Kinetics of anti-SARS-CoV-2 antibody
557 responses 3 months post complete vaccination with BNT162b2; A prospective
558 study in 283 health workers. *Cells* 10:1942.
- 559 43. Centers for Disease Control and Prevention. 2020. National diabetes statistic
560 report, 2020. [https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-](https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf)
561 [statistics-report.pdf](https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf). Accessed 24 Nov 2021.
- 562 44. Ostchega R, Fyar C, Nwanko T, Nguyen D. 2020. Hypertension prevalence
563 among adults aged 18 and over: United States, 2017–2018. *NCHS Data Brief*
564 364:1–8.
- 565 45. Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB,
566 Tan BKJ, Chan YH, Sundar R, Soon YY. 2022. Efficacy of covid-19 vaccines in
567 immunocompromised patients: systematic review and meta-analysis. *BMJ*
568 376:e068632.

569 **Tables and figures for ms**

570 Table 1: Demographics of the donors from the Boca Biolistics panel

571

Characteristics	All N=56	Pfizer n=34	Moderna n=22
Male/female, %	44.64/55.36	44.12/55.88	45.45/54.55
Median age, IQR	70 (61.75–72)	70 (63–71.75)	71 (57.25–73)
Ethnicity, %			
Asian; Not Hispanic/Latino,	1.79	2.94	0
Black/African American; Not Hispanic/Latino	3.57	5.88	0
White/Caucasian; Not Hispanic/Latino	64.29	61.76	68.18
Hispanic/Latino; Black/African American	7.14	8.82	4.55
Hispanic/Latino; White/Caucasian	23.21	20.59	27.27
Pre-existing medical conditions, %			
Yes/No	51.79/48.21	50.00/50.00	54.55/45.45
Hypertension, Yes/No	60.71/39.29	35.29/64.71	54.55/45.45

Diabetes mellitus, Yes/No	7.14/92.86	11.76/88.24	0/100
---------------------------	------------	-------------	-------

572 IQR, interquartile range

573 Table 2: Agreement between SARS-CoV-2 Rapid Antibody Test (IgG and IgM) and Elecsys Anti-SARS-CoV-2 S assay (reference
 574 test) qualitative measurements as measured by lot and evaluator using the Boca Biolistics donor panel, and after one dose or at
 575 least 14 days after two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2

576

		mRNA-1273								BNT162b2							
		1 dose				2 doses				1 dose				2 doses			
		Evaluator 1		Evaluator 2		Evaluator 1		Evaluator 2		Evaluator 1		Evaluator 2		Evaluator 1		Evaluator 2	
		Lot 1	Lot 2	Lot 1	Lot 2	Lot 1	Lot 2	Lot 1	Lot 2	Lot 1	Lot 2	Lot 1	Lot 2	Lot 1	Lot 2	Lot 1	Lot 2
Ig G	N	5	5	5	5	19	19	19	19	8	8	8	8	34	34	34	34
	N +	5	5	5	5	19	19	19	19	7	7	7	7	34	34	34	34
	N -	-	-	-	-	-	-	-	-	1*	1*	1*	1*	-	-	-	-
	TP	5	5	5	5	19	19	19	19	7	7	7	7	34	34	33	33
	FN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	PPA, %	100	100	100	100	100	100	100	100	100	100	100	100	100	100	97.0	97.0
	lower	47.82	47.82	47.82	47.82	82.3	82.3	82.3	82.3	59.0	59.0	59.0	59.0	89.7	89.7	84.6	84.6


	CI																
	upper CI	100	100	100	100	100	100	100	100	100	100	100	100	100	100	99.93	99.93
Ig M	N	5	5	5	5	19	19	19	19	8	8	8	8	34	34	34	34
	N +	5	5	5	5	19	19	19	19	7	7	7	7	34	34	34	34
	N -	-	-	-	-	-	-	-	-	1*	1*	1*	1*	-	-	-	-
	TP	1	1	4	3	4	4	6	4	2	2	3	2	6	6	5	5
	FN	4	4	1	2	15	15	13	15	5	5	4	5	28	28	29	29
	PPA, %	20.00	20.00	80.00	60.00	21.05	21.05	31.58	21.05	28.57	28.57	42.86	28.57	17.65	17.65	14.71	14.71
	lower CI	0.51	0.51	28.36	14.66	6.05	6.05	12.58	6.05	3.67	3.67	9.9	3.67	6.76	6.76	4.95	4.95
	upper CI	71.64	71.64	99.49	94.73	45.57	45.57	56.55	45.57	70.96	70.96	81.59	70.96	34.53	34.53	31.06	31.06

577 *1 sample was detected as antibody-negative by the Elecsys Anti-SARS-CoV-2 S and the SARS-CoV-2 Rapid Antibody Test.

578 +, positive by the reference test (Elecsys Anti-SARS-CoV-2 S assay); -, negative by the reference test (Elecsys Anti-SARS-CoV-2

579 S assay); CI, 95% confidence intervals; TP, true-positive; FN, false-negative; PPA, positive percent agreement

580 Figure 1: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgG vs Elecsys Anti-
581 SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-
582 1273 (left panel) or Pfizer-BioNTech BNT162b2 (right panel) at least 14 days
583 following second dose




584
585

586 Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or
587 one of the five levels of increasing positivity based upon line intensity (((+)), (+), +,
588 ++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was
589 25,000 U/mL. Higher values are indicated as >25,000 U/mL. Blue = Lot 1; red = Lot
590 2; ○ = Evaluator 1; + = Evaluator 2.

591

592 Figure 2: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgM vs Elecsys Anti-
593 SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-
594 1273 (left panel) or Pfizer-BioNTech BNT162b2 (right panel) at least 14 days
595 following second dose



596
597 Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or
598 one of the five levels of increasing positivity based upon line intensity (((+)), (+), +,
599 ++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was
600 25,000 U/mL. Higher values are indicated as >25,000 U/mL. Blue = Lot 1; red = Lot
601 2; ○ = Evaluator 1; + = Evaluator 2.

602

